Shenzhen Stock Exchange issued an inquiry letter to Haiwang Bio for 2022 annual report asking for additional explanation on the reasonableness of goodwill impairment during the reporting period.

[Shenzhen Stock Exchange issued a letter of inquiry on the 2022 annual report to Haiwang Bio to supplement the reasonableness of the impairment of goodwill in the reporting period] the Shenzhen Stock Exchange issued a letter of inquiry on the 2022 annual report to Haiwang Bio on May 9. It is required to list the details of subsidiaries related to goodwill impairment in the reporting period, including, but not limited to, operating income, net profit, cash flow of operating activities, current amount and year-on-year changes in the previous period. Add the basis and rationality of the goodwill impairment test process, the important hypotheses of the impairment test, the selection basis and rationality of the key parameters (including but not limited to the forecast period, income growth rate, expense rate, profit margin, discount rate, etc.). Whether there is a big difference, reason and rationality in the selection of key parameters between this period and 2020 and 2021.